par Deltenre, Pierre
;Berson, A;Marcellin, P;Degott, C;Biour, M;Pessayre, D
Référence Gut, 44, 6, page (886-888)
Publication Publié, 1999-06
;Berson, A;Marcellin, P;Degott, C;Biour, M;Pessayre, DRéférence Gut, 44, 6, page (886-888)
Publication Publié, 1999-06
Article révisé par les pairs
| Résumé : | Treatment of ulcerative colitis or Crohn's disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported. |



